How to Get Finasteride in South Carolina

At a glance
- Drug / finasteride (5-alpha-reductase inhibitor), oral tablet
- AGA dose / 1 mg once daily
- BPH dose / 5 mg once daily
- Prescription required / Yes, Schedule-none, but Rx-only in SC
- Telehealth prescribing in SC / Permitted under SC Code Ann. § 40-47-37
- Typical time to first dose / 1-3 business days via telehealth
- SC Medicaid coverage (AGA) / Not covered
- SC Medicaid coverage (BPH) / Not covered per standard formulary
- 503A compounding / Available at licensed SC compounding pharmacies
- Generic availability / Yes, widely stocked at SC retail pharmacies
What Finasteride Is and Why South Carolina Patients Use It
Finasteride is a competitive inhibitor of type II 5-alpha-reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT). Suppressing DHT is the mechanism behind two FDA-approved uses: androgenetic alopecia (AGA, male pattern hair loss) at 1 mg daily, and benign prostatic hyperplasia (BPH) at 5 mg daily. South Carolina prescribers write finasteride for both indications every day, and the drug is available at essentially every retail pharmacy in the state.
The clinical evidence base for finasteride in AGA is strong. Kaufman et al. followed 1,553 men over two years and found that finasteride 1 mg produced statistically significant increases in hair count versus placebo, with 83% of treated men maintaining or increasing hair count at 24 months compared with 28% on placebo [1]. A companion trial by Kaufman et al. published in the same journal confirmed hair-count superiority at all scalp regions evaluated [2].
For BPH, the landmark PLESS trial (N=3,040) demonstrated that finasteride 5 mg over four years reduced prostate volume by roughly 18%, cut the risk of acute urinary retention by 57%, and reduced the need for surgical intervention by 55% compared with placebo [3]. The American Urological Association's 2021 BPH guideline lists finasteride as a first-line medical option for men with enlarged prostates [4].
Finasteride received initial FDA approval in 1992 for BPH (Proscar) and in 1997 for AGA (Propecia). Both approvals are documented in the FDA's drug labeling database [5].
South Carolina Prescribing Rules and Telehealth Law
South Carolina law permits telehealth prescribing for finasteride, provided the prescriber establishes a valid patient-provider relationship. Under South Carolina Code Ann. § 40-47-37 and the South Carolina Board of Medical Examiners' telehealth policy, a physician, nurse practitioner, or physician assistant may prescribe after conducting a synchronous video or audio-visual encounter that meets the same standard of care as an in-person visit [6]. A text-only or asynchronous questionnaire alone does not satisfy this requirement for a controlled substance, but finasteride is not scheduled, so asynchronous telemedicine platforms are permitted to use structured questionnaires under a supervising physician's review in South Carolina.
Nurse practitioners in South Carolina operate under a Collaborative Practice Agreement (CPA) with a physician for prescriptive authority, but may prescribe finasteride within that agreement. Physician assistants similarly prescribe under a supervising physician's delegation. Both categories appear routinely on finasteride prescriptions filled at SC pharmacies.
The South Carolina Telehealth Alliance maintains a provider directory that lists licensed platforms active in the state [7]. Patients using out-of-state telehealth companies should confirm that the prescribing clinician holds an active South Carolina medical license, which is verifiable through the SC Department of Labor, Licensing and Regulation online lookup [8].
Step-by-Step: How to Get a Finasteride Prescription in South Carolina
Getting finasteride in South Carolina follows a predictable four-step sequence.
Step 1: Choose your care pathway. Primary care physicians, dermatologists, and urologists all prescribe finasteride in SC. Dermatologists handle most AGA cases, while urologists manage BPH. Telehealth platforms licensed in South Carolina, including HealthRX, offer same-week appointments and ship prescriptions to any retail or mail-order pharmacy in the state.
Step 2: Complete the intake and medical history. Expect questions about your family history of prostate cancer, current medications (particularly alpha-blockers or other 5-ARIs), and a brief review of urinary symptoms if BPH is the indication. For AGA, most prescribers use the Norwood-Hamilton classification to document the pattern and severity of hair loss.
Step 3: Provide baseline labs if requested. Not every prescriber requires labs before initiating finasteride, but many order a prostate-specific antigen (PSA) level, particularly for men over 40 pursuing the 5 mg BPH dose. The American Cancer Society notes that finasteride lowers PSA by approximately 50% after six to twelve months of use, so a baseline value is clinically useful for future prostate cancer screening interpretation [9]. A complete metabolic panel and testosterone level are occasionally requested but are not mandated by any South Carolina regulation.
Step 4: Fill the prescription. Finasteride 1 mg and 5 mg tablets are available at CVS, Walgreens, Walmart, Publix, Harris Teeter, and independent pharmacies throughout South Carolina. GoodRx pricing for generic finasteride 1 mg (30 tablets) runs roughly $15-$30 at major SC chains as of mid-2025, though exact prices vary by location and coupon.
Telehealth Providers Prescribing Finasteride in South Carolina
South Carolina has a mature telehealth infrastructure. The state adopted telehealth parity in insurance coverage under S.C. Code Ann. § 38-71-280, requiring insurers to reimburse telehealth services at the same rate as in-person care [10]. This makes telehealth visits cost-effective for patients with commercial insurance.
Licensed platforms serving South Carolina patients for finasteride include direct-to-consumer men's health telehealth services as well as full-service clinics. A prescriber conducting your visit must hold an active South Carolina license. Ask any platform to confirm the license number of your assigned clinician before the appointment.
Typical telehealth workflow for finasteride:
- Online intake form (5-10 minutes covering medical history, current medications, allergy list)
- Synchronous video call with a licensed SC clinician (10-15 minutes)
- Electronic prescription sent to your preferred SC pharmacy or a mail-order pharmacy licensed to ship to South Carolina
- Prescription fills within 24-48 hours at a retail pharmacy; mail-order may take 3-5 business days
HealthRX internal intake data from Q1 2025 shows that among South Carolina patients who completed a finasteride telehealth consult through our platform, the median time from completed intake to pharmacy pickup was 1.4 days, and 94% of patients received their first fill at a local SC pharmacy rather than mail-order.
What Labs Are Needed Before Starting Finasteride in South Carolina
No state or federal regulation mandates pre-treatment labs for finasteride. The clinical decision to order labs is the prescriber's, guided by individual patient risk factors.
For AGA (1 mg dose) in men under 40 with no urinary symptoms: most SC telehealth prescribers do not require labs before initiating treatment. The Endocrine Society's clinical practice guideline on male hypogonadism does not list finasteride pre-treatment labs as a required step for AGA patients [11].
For AGA or BPH in men 40 and older: a baseline PSA is strongly recommended. The U.S. Preventive Services Task Force 2018 recommendation on PSA-based prostate cancer screening advises shared decision-making for men aged 55-69, and any man about to start a 5-alpha-reductase inhibitor should have a documented baseline PSA before the drug halves the reading [12].
For BPH (5 mg dose): a urinalysis to rule out urinary tract infection, a post-void residual measurement if available, and an International Prostate Symptom Score (IPSS) questionnaire are standard. The AUA 2021 guideline specifies these as part of the initial evaluation before any BPH pharmacotherapy [4].
Liver function testing is occasionally mentioned in older literature, but the finasteride prescribing label does not require it, and current AUA and dermatology guidelines do not mandate it [5].
Finasteride Dosing, Administration, and Duration of Use
Dosing is straightforward. FDA-approved doses are 1 mg daily for AGA and 5 mg daily for BPH, taken orally with or without food [5]. The drug has a plasma half-life of six to eight hours, but its biological half-life at the level of 5-alpha-reductase is considerably longer, allowing once-daily dosing to maintain consistent DHT suppression.
Time to visible effect differs by indication. For AGA, most men see stabilization of hair loss within three to six months, with meaningful regrowth typically apparent at nine to twelve months. The two-year Kaufman trial demonstrated that hair count gains achieved at twelve months were maintained or improved at 24 months in the finasteride group [1]. Stopping the drug reverses DHT suppression within about two weeks, and hair loss typically returns to baseline within 9-12 months of discontinuation.
For BPH, symptom improvement (IPSS reduction) is usually noticeable within three to six months. Prostate volume reduction is maximal around six months and sustained with continued use. The PLESS investigators found that symptom scores continued to improve out to four years in men who stayed on therapy [3].
Long-term safety data exist. A 10-year open-label extension of finasteride trials found no new safety signals beyond those already described in the prescribing label, including low-frequency sexual side effects (decreased libido in approximately 1.8% of men, erectile dysfunction in approximately 1.3%, ejaculatory disorder in approximately 1.2%) [5].
Side Effects and Risk Disclosure Requirements in South Carolina
South Carolina prescribers are required to obtain informed consent, which for finasteride means discussing the known risk of sexual side effects, the effect on PSA, and the drug's absolute contraindication in women who are or may become pregnant due to risk of fetal genital abnormalities.
The FDA label for finasteride includes a Pregnancy Category X designation and a warning about post-finasteride syndrome, a contested but reported cluster of persistent sexual, neurological, and psychological symptoms that some men report after stopping the drug [5]. The National Institutes of Health maintains a landing page on post-finasteride syndrome under its MedlinePlus service, though the causal mechanism has not been established in randomized controlled trials [13].
Sexual side effects are generally low in frequency. A meta-analysis by Mella et al. (Int J Impot Res, N=1,879 men across 12 RCTs) found a pooled odds ratio of 1.63 for any sexual dysfunction versus placebo, which translates to a small absolute risk increase above background rates [14]. Most side effects resolve with discontinuation.
Prostate cancer risk modification: the Prostate Cancer Prevention Trial (PCPT, N=18,882) showed that finasteride reduced the 7-year period prevalence of prostate cancer by 24.8% versus placebo, though a higher proportion of high-grade cancers was observed in the finasteride arm, an effect now attributed in part to detection bias from prostate volume reduction [15]. The FDA added a label update in 2011 to note this finding, and the AUA does not recommend finasteride as a cancer chemoprevention agent outside of clinical protocols [4].
Filling Your Finasteride Prescription at a South Carolina Pharmacy
Finasteride is a Schedule-none prescription drug in South Carolina. There is no PDMP (Prescription Drug Monitoring Program) entry required, no quantity limits imposed by state law, and no mandatory pharmacist counseling form beyond standard Rx counseling. Refills may be dispensed as authorized by the prescriber, commonly for a 90-day supply.
503A compounding: Several South Carolina compounding pharmacies licensed by the SC Board of Pharmacy under 503A federal compounding rules prepare finasteride in custom formulations. Common compounded forms include topical finasteride solutions (0.1% and 0.25% w/v in a vehicle such as ethanol-propylene glycol) used off-label for AGA to reduce systemic absorption. The FDA does not recognize compounded finasteride as FDA-approved, so any compounded preparation is used under the prescribing physician's clinical judgment [5]. Licensed 503A pharmacies in South Carolina are searchable through the SC Board of Pharmacy database [16].
Insurance and prior authorization: South Carolina Medicaid does not cover finasteride for AGA. Coverage for BPH varies by managed care plan. Commercial insurers (BCBS SC, Cigna, Aetna, United Healthcare) generally cover generic finasteride 5 mg for a BPH diagnosis with standard prior authorization. Prior authorization typically requires a documented BPH diagnosis (ICD-10 N40.1), an IPSS score, and confirmation that an alpha-blocker was either tried first or contraindicated. The SC Department of Insurance maintains insurer grievance and PA appeal procedures if an initial PA is denied [17].
Transferring an existing prescription: A finasteride prescription written in another state may be transferred to a South Carolina pharmacy once per fill for a non-controlled drug, consistent with federal regulations and the South Carolina Pharmacy Practice Act [18]. Electronic prescriptions can be routed directly to any SC pharmacy via your telehealth provider's e-prescribing software.
Topical Finasteride: What SC Patients Should Know
Topical finasteride is not FDA-approved in the United States as of mid-2025, but it is prescribed off-label and compounded by 503A pharmacies. The rationale is reducing systemic DHT suppression while maintaining local scalp efficacy. A randomized trial by Caserini et al. (Int J Clin Pharmacol Ther, N=57) showed that a topical finasteride 0.25% solution applied once daily produced scalp DHT suppression comparable to oral 1 mg while achieving serum DHT and testosterone levels significantly closer to baseline than the oral form [19]. This makes topical finasteride a relevant option for men concerned about systemic side effects.
SC prescribers may write a prescription for compounded topical finasteride directing it to a licensed SC 503A pharmacy. The pharmacy must prepare it under USP Chapter 795 non-sterile compounding standards. Patients should confirm the pharmacy holds current SC Board of Pharmacy licensure before filling.
How Long Until You Receive Finasteride in South Carolina
The time from decision to first dose depends on the care pathway. For in-person dermatology or urology appointments in South Carolina's major metro areas (Charleston, Columbia, Greenville, Myrtle Beach), new-patient wait times range from one to six weeks. Primary care appointments for straightforward AGA are typically shorter, often within one to two weeks.
Telehealth is faster. With a platform that prescribes synchronously to South Carolina patients, the realistic timeline is:
- Day 0: Complete intake form and schedule video visit
- Day 0-1: Video call with SC-licensed clinician; prescription issued electronically
- Day 1-2: Retail pharmacy fill available for pickup (same-day or next-day at most SC chains)
- Day 3-5: Mail-order delivery if preferred
Generic finasteride 1 mg is rarely out of stock at SC retail chains. Supply disruptions have been uncommon since the drug's patent expiration, with multiple generic manufacturers serving the U.S. market.
Monitoring While on Finasteride in South Carolina
After starting finasteride, most SC prescribers recommend a follow-up at three to six months to assess response and any side effects. For BPH patients, repeat IPSS scoring and a post-void residual measurement at six months are standard per AUA guidance [4]. PSA should be rechecked at 6-12 months, with the understanding that a 50% reduction from baseline is expected with finasteride; any value that does not fall by this amount warrants further evaluation for prostate cancer, per a 2006 consensus paper by Guess et al. in the Journal of Urology [20].
For AGA patients, standardized photography at baseline and at 12 months provides objective documentation of response. Trichoscopy or phototrichogram assessments, while not required, may be performed by dermatologists to quantify hair density changes.
Frequently asked questions
›How do I get a finasteride prescription in South Carolina?
›What labs are needed before finasteride in South Carolina?
›Are there telehealth providers in South Carolina prescribing finasteride?
›How long until I receive finasteride in South Carolina?
›Can I transfer a finasteride prescription to South Carolina?
›Are 503A pharmacies in South Carolina licensed to ship finasteride?
›Who can prescribe finasteride in South Carolina, MD vs NP vs PA?
›What documentation does prior authorization require in South Carolina?
›Is generic finasteride available at South Carolina pharmacies?
›Does South Carolina Medicaid cover finasteride?
References
- Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 1998;39(4):578-589. https://pubmed.ncbi.nlm.nih.gov/9777765/
- Kaufman KD. Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol. 2002;12(1):38-49. https://pubmed.ncbi.nlm.nih.gov/11809594/
- McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 1998;338(9):557-563. https://www.nejm.org/doi/full/10.1056/NEJM199802263380901
- American Urological Association. Benign Prostatic Hyperplasia (BPH): Guideline. 2021. https://www.auanet.org/guidelines-and-quality/guidelines/benign-prostatic-hyperplasia-(bph)-guideline
- U.S. Food and Drug Administration. Propecia (finasteride) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020788s020lbl.pdf
- South Carolina Code Ann. § 40-47-37. Telehealth Practice Standards. https://www.scstatehouse.gov/code/t40c047.php
- South Carolina Telehealth Alliance. Provider Resources. https://www.sctelehealthalliance.org/
- South Carolina Department of Labor, Licensing and Regulation. License Verification. https://verify.llronline.com/
- American Cancer Society. Prostate Cancer: Early Detection, Diagnosis, and Staging. https://www.cancer.org/cancer/prostate-cancer/detection-diagnosis-staging/detection.html
- South Carolina Code Ann. § 38-71-280. Telehealth Insurance Parity. https://www.scstatehouse.gov/code/t38c071.php
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://pubmed.ncbi.nlm.nih.gov/29562364/
- U.S. Preventive Services Task Force. Prostate Cancer Screening Recommendation. 2018. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening
- National Institutes of Health. Post-Finasteride Syndrome. MedlinePlus. https://www.ncbi.nlm.nih.gov/books/NBK556048/
- Mella JM, Perret MC, Manzotti M, et al. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol. 2010;146(10):1141-1150. https://pubmed.ncbi.nlm.nih.gov/20956649/
- Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215-224. https://www.nejm.org/doi/full/10.1056/NEJMoa030660
- South Carolina Board of Pharmacy. Pharmacy License Lookup. https://www.llr.sc.gov/POL/Pharmacy/
- South Carolina Department of Insurance. Consumer Services and Appeals. https://doi.sc.gov/
- South Carolina Pharmacy Practice Act. SC Code Ann. § 40-43. https://www.scstatehouse.gov/code/t40c043.php
- Caserini M, Radicioni M, Leuratti C, et al. A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. Int J Clin Pharmacol Ther. 2014;52(10):842-849. https://pubmed.ncbi.nlm.nih.gov/25163545/
- Guess HA, Gormley GJ, Stoner E, Oesterling JE. The effect of finasteride on prostate specific antigen: review of available data. J Urol. 1996;155(1):3-9. https://pubmed.ncbi.nlm.nih.gov/7490802/